ARCHIVES

Six-Year Follow Up Of Phase III Sprycel Trial Demonstrates 71 Percent Overall Survival

This article is from The Cancer Letter archive.

Vol. 35 No. 7 | July 27, 2012

Download PDF Visit The Full Archive

Related Articles

Drug Development: Tivozanib Trial Discontinued Due to Insufficient Enrollment

February 7, 2014

Swedish Study Finds Long Term Hormonal Therapy May Increase Breast Cancer Risk

August 4, 1989

In Brief: Ira Kline, NCI researcher, Dead At 69; Massey Recruits Scientists; ACR Awards

October 15, 1993

House Panel Targets AWP For Medicare Drug Pricing.

October 5, 2001

Advisors Voted For Provenge Approval Despite Fundamental Flaws In Trials.

April 13, 2007

ACS Awards $54 Million in Research Grants.

October 31, 2008